Q-omics provides the consensus-scored MAGEA12 profile across patient tissues and cancer cell-line models. MAGEA12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MAGEA12 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, MAGEA12 mutation status shows 6,752 significant gene co-expression associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRP, HNSC, and UCEC as cancer lineages where MAGEA12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAGEA12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAGEA12 survival associations across molecular data types. MAGEA12 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAGEA12 RNA expression–survival associations across cancer types. High MAGEA12 expression shows unfavorable associations in KIRP, COAD and LIHC, but favorable associations in PAAD, BLCA and DLBC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MAGEA12 RNA expression.
This table summarizes MAGEA12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MAGEA12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAGEA12 shows higher tumor expression in HNSC, LUAD, LIHC, LUSC, BRCA and KIRC. The HNSC box plot shows higher MAGEA12 RNA expression in tumor versus normal tissue (log2 FC = +1.402, t-test p < 0.001).
This table shows molecular features associated with MAGEA12 in patient tissues and cancer cell lines. In patient samples, MAGEA12 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAGEA12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LIVER.
